Ubrogepant, also known as MK-1602, is a potent and selective oral calcitonin gene-related peptide (CGRP) receptor antagonist. Ubrogepant has completed Phase II clinical trials for acute treatment of migraines.
台州市科瑞生物技术有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
crene